Selexipag as a Therapeutic Alternative for Treprostinil‐Induced Thrombocytopenia in Pulmonary Arterial Hypertension: A Case Report
Parenteral prostacyclin pathway agent-induced thrombocytopenia may require dose reduction or therapy discontinuation to mitigate the adverse events. However, the pulmonary arterial hypertension (PAH) guidelines do not suggest any strategy to overcome treprostinil-induced thrombocytopenia. Selexipag is an oral, non-prostanoid, selective IP receptor agonist. This is the first case report proposing the use of selexipag, due to its minimal thrombocytopenia risk, when severe treprostinil-induced thrombocytopenia occurs in practice. A 66-year-old woman presented to the hospital with new-onset PAH and right ventricular dysfunction. Due to the high mortality risk, the patient was initially started on intravenous treprostinil. The clinical course was complicated by probable treprostinil-induced thrombocytopenia. Due to the need for prostacyclin pathway therapy, the decision was made to switch from intravenous treprostinil to oral selexipag. The nadir platelet count was 30,000/μL. Approximately 72 h after discontinuation of treprostinil and maintaining selexipag 1600 mcg twice daily, the platelet count improved to 46,000/μL on the day of discharge. Several days after discharge, the platelet count further improved to 55,000/μL. The repeated platelet count 1 month after discharge normalized to 329,000/μL. Our case report described the successful use of selexipag to overcome treprostinil-induced thrombocytopenia, owing to its limited effect on platelet aggregation.
Authors
- Marco A. Caccamo (ORCID: https://orcid.org/0000-0001-8534-0474)
- Kazuhiko Kido (ORCID: https://orcid.org/0000-0002-3393-8025)
- George G. Sokos (ORCID: https://orcid.org/0000-0001-7421-0148)
- James C. Coons (ORCID: https://orcid.org/0000-0002-7193-3751)
- Anantha Madgula
Institutions
- West Virginia University (US)
- University of Pittsburgh (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1002/phar.70222
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00